Cargando…

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

The need for solid clinical definitions of resistance to programmed death 1 or its ligand (PD-(L)1) inhibitors for clinical trial design was identified as a priority by the Society for Immunotherapy of Cancer (SITC). Broad consensus efforts have provided definitions for primary and secondary resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Tawbi, Hussein A, Sullivan, Ryan J, Feltquate, David, LaVallee, Theresa, Rizvi, Naiyer A, Sharon, Elad, Sosman, Jeffrey, Kluger, Harriet M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373737/
https://www.ncbi.nlm.nih.gov/pubmed/37487665
http://dx.doi.org/10.1136/jitc-2023-007309
_version_ 1785078624078004224
author Tawbi, Hussein A
Sullivan, Ryan J
Feltquate, David
LaVallee, Theresa
Rizvi, Naiyer A
Sharon, Elad
Sosman, Jeffrey
Kluger, Harriet M
author_facet Tawbi, Hussein A
Sullivan, Ryan J
Feltquate, David
LaVallee, Theresa
Rizvi, Naiyer A
Sharon, Elad
Sosman, Jeffrey
Kluger, Harriet M
author_sort Tawbi, Hussein A
collection PubMed
description The need for solid clinical definitions of resistance to programmed death 1 or its ligand (PD-(L)1) inhibitors for clinical trial design was identified as a priority by the Society for Immunotherapy of Cancer (SITC). Broad consensus efforts have provided definitions for primary and secondary resistance and resistance after stopping therapy for both single-agent PD-(L)1 inhibitors and associated combinations. Validation of SITC’s definitions is critical and requires field-wide data sharing and collaboration. Here, in this commentary, we detail current utility and incorporation of SITC’s definitions and discuss the next steps both the society and the field must take to further advance immuno-oncology drug development.
format Online
Article
Text
id pubmed-10373737
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-103737372023-07-28 Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development Tawbi, Hussein A Sullivan, Ryan J Feltquate, David LaVallee, Theresa Rizvi, Naiyer A Sharon, Elad Sosman, Jeffrey Kluger, Harriet M J Immunother Cancer Commentary The need for solid clinical definitions of resistance to programmed death 1 or its ligand (PD-(L)1) inhibitors for clinical trial design was identified as a priority by the Society for Immunotherapy of Cancer (SITC). Broad consensus efforts have provided definitions for primary and secondary resistance and resistance after stopping therapy for both single-agent PD-(L)1 inhibitors and associated combinations. Validation of SITC’s definitions is critical and requires field-wide data sharing and collaboration. Here, in this commentary, we detail current utility and incorporation of SITC’s definitions and discuss the next steps both the society and the field must take to further advance immuno-oncology drug development. BMJ Publishing Group 2023-07-24 /pmc/articles/PMC10373737/ /pubmed/37487665 http://dx.doi.org/10.1136/jitc-2023-007309 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Commentary
Tawbi, Hussein A
Sullivan, Ryan J
Feltquate, David
LaVallee, Theresa
Rizvi, Naiyer A
Sharon, Elad
Sosman, Jeffrey
Kluger, Harriet M
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
title Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
title_full Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
title_fullStr Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
title_full_unstemmed Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
title_short Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
title_sort society for immunotherapy of cancer (sitc) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373737/
https://www.ncbi.nlm.nih.gov/pubmed/37487665
http://dx.doi.org/10.1136/jitc-2023-007309
work_keys_str_mv AT tawbihusseina societyforimmunotherapyofcancersitccheckpointinhibitorresistancedefinitionseffortstoharmonizeterminologyandaccelerateimmunooncologydrugdevelopment
AT sullivanryanj societyforimmunotherapyofcancersitccheckpointinhibitorresistancedefinitionseffortstoharmonizeterminologyandaccelerateimmunooncologydrugdevelopment
AT feltquatedavid societyforimmunotherapyofcancersitccheckpointinhibitorresistancedefinitionseffortstoharmonizeterminologyandaccelerateimmunooncologydrugdevelopment
AT lavalleetheresa societyforimmunotherapyofcancersitccheckpointinhibitorresistancedefinitionseffortstoharmonizeterminologyandaccelerateimmunooncologydrugdevelopment
AT rizvinaiyera societyforimmunotherapyofcancersitccheckpointinhibitorresistancedefinitionseffortstoharmonizeterminologyandaccelerateimmunooncologydrugdevelopment
AT sharonelad societyforimmunotherapyofcancersitccheckpointinhibitorresistancedefinitionseffortstoharmonizeterminologyandaccelerateimmunooncologydrugdevelopment
AT sosmanjeffrey societyforimmunotherapyofcancersitccheckpointinhibitorresistancedefinitionseffortstoharmonizeterminologyandaccelerateimmunooncologydrugdevelopment
AT klugerharrietm societyforimmunotherapyofcancersitccheckpointinhibitorresistancedefinitionseffortstoharmonizeterminologyandaccelerateimmunooncologydrugdevelopment